Nanoparticle-enhanced proton beam immunoradiotherapy drives immune activation and durable tumor rejection.

JCI Insight · 2023 · PMC10371249 · PMID 37345658

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a marked trendno p-value reported

However, this was not observed when compared to the tumors treated with PBT+αPD1, despite a marked trend.

also in 109 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.